ArticleActa neuropathologica2023
Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.
Open access · hybridAbstract read
In one paragraph
Article in Acta neuropathologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 20 citations in OpenAlex.
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- Genetic orchestration of the primary central nervous system lymphoma microenvironment.Biomarker research · 2026Review
- Primary central nervous system lymphoma in the molecular era: genomic drivers, liquid biopsy, and targeted therapeutic strategies.Annals of hematology · 2026Review
- Article
- Time Is Key: Early Diagnosis of Post-Transplant Lymphoproliferative Disorder Presenting as Primary CNS Diffuse Large B-Cell Lymphoma.Current oncology (Toronto, Ont.) · 2026Article
- Unraveling the immune microenvironment in primary CNS lymphoma.Biomarker research · 2026Review
- Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.Blood neoplasia · 2026Article
- Article
- Genomic landscape and molecular subtypes of primary central nervous system lymphoma.Blood cancer journal · 2025Article
- A nomogram for predicting the diagnosis of central malignant tumors based on preoperative clinical characteristics and laboratory indicators: a diagnostic study.International journal of surgery (London, England) · 2025Article
- Genomic landscape of virus-associated cancers.Nature communications · 2025Article
- Article
- Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas.Neuro-oncology · 2025Article
- Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments.Haematologica · 2024Article
- Factors influencing timely diagnosis in neurolymphomatosis.Journal of neuro-oncology · 2024Article
- Primary central nervous system lymphomas in immunocompromised patients require specific response criteria.Journal of neuro-oncology · 2024Article
- Extranodal lymphoma: pathogenesis, diagnosis and treatment.Molecular biomedicine · 2023Review
- The specific DNA methylation landscape in focal cortical dysplasia ILAE type 3D.Acta neuropathologica communications · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Leon D Kaulen *Department of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany. leon.kaulen@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-5937-3376
Evgeniya Denisova *Division of Applied Bioinformatics, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-6258-8055
Felix HinzDepartment of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Ling HaiClinical Cooperation Unit (CCU) Neuro-Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8719-2727
Dennis FriedelDepartment of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Octavian HenegariuDepartment of Neurosurgery, Yale School of Medicine, New Haven, USA.ORCID http://orcid.org/0000-0002-8971-1049
Dirk C HoffmannDepartment of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1370-1933
Jakob ItoClinical Cooperation Unit (CCU) Neuro-Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Alexandros KourtesakisClinical Cooperation Unit (CCU) Neuro-Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7894-9131
Pascal LehnertClinical Cooperation Unit (CCU) Neuro-Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Sofia DoubrovinskaiaDepartment of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4470-8396
Philipp KarschniaDepartment of Neurosurgery, Munich University Hospital, Ludwig Maximilians University (LMU) Munich, and German Cancer Consortium (DKTK) Partner Site, Munich, Germany.ORCID http://orcid.org/0000-0002-1254-5310
Louisa von BaumgartenDepartment of Neurosurgery, Munich University Hospital, Ludwig Maximilians University (LMU) Munich, and German Cancer Consortium (DKTK) Partner Site, Munich, Germany.ORCID http://orcid.org/0000-0002-6634-0927
Tobias KesslerDepartment of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8350-7074
Joachim M BaehringDepartment of Neurosurgery, Yale School of Medicine, New Haven, USA.ORCID http://orcid.org/0000-0001-7755-6793
Benedikt BrorsDivision of Applied Bioinformatics, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5940-3101
Felix SahmDepartment of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany. felix.sahm@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0001-5441-1962
Wolfgang WickDepartment of Neurology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-6171-634X
German Cancer Research Center · DEDeutschen Konsortium für Translationale Krebsforschung · DEHeidelberg University · DEYale University · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCATS NIH HHS UL1 TR001863
Abstract
Immunodeficiency-associated primary CNS lymphoma (PCNSL) represents a distinct clinicopathological entity, which is typically Epstein-Barr virus-positive (EBV
Indexed as
Epstein-Barr Virus InfectionsLymphomaHerpesvirus 4, HumanHumansMutationPrognosisTumor MicroenvironmentEpstein-Barr virusExome sequencingGeneticsImmunodeficiencyNon-Hodgkin lymphomaPrimary CNS lymphomaRNA sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.